91 related articles for article (PubMed ID: 847382)
21. Thrombophilic abnormalities of natural anticoagulants in patients with ulcerative colitis.
Zezos P; Papaioannou G; Nikolaidis N; Vasiliadis T; Giouleme O; Evgenidis N
Hepatogastroenterology; 2007; 54(77):1417-21. PubMed ID: 17708267
[TBL] [Abstract][Full Text] [Related]
22. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial.
Hanauer SB; Sandborn WJ; Kornbluth A; Katz S; Safdi M; Woogen S; Regalli G; Yeh C; Smith-Hall N; Ajayi F
Am J Gastroenterol; 2005 Nov; 100(11):2478-85. PubMed ID: 16279903
[TBL] [Abstract][Full Text] [Related]
23. Active idiopathic ulcerative colitis in a patient with ongoing HIV-related immunodepression.
Bernstein CN; Snape WJ
Am J Gastroenterol; 1991 Jul; 86(7):907-9. PubMed ID: 1676240
[TBL] [Abstract][Full Text] [Related]
24. Elevated markers of thrombin generation and fibrinolysis in patients with active and quiescent ulcerative colitis.
Zezos P; Papaioannou G; Nikolaidis N; Patsiaoura K; Vassiliadis T; Mpoumponaris A; Giouleme O; Evgenidis N
Med Sci Monit; 2009 Nov; 15(11):CR563-72. PubMed ID: 19865055
[TBL] [Abstract][Full Text] [Related]
25. The in vitro effect of corticosteroids on T-lymphocyte subpopulations in patients with ulcerative colitis.
Nikolopoulou VN; Gogos CA; Zoumbos NC
Z Gastroenterol; 1990 Feb; 28(2):101-3. PubMed ID: 2138831
[TBL] [Abstract][Full Text] [Related]
26. Subnormal activation of phagocytes by complement in chronic inflammatory bowel disease? Neutrophil chemotaxis to complement split product C5a.
Elmgreen J
Gut; 1984 Jul; 25(7):737-42. PubMed ID: 6735255
[TBL] [Abstract][Full Text] [Related]
27. Increased colonic adenylate cyclase activity in active ulcerative colitis.
Rachmilewitz D; Karmeli F; Selinger Z
Gastroenterology; 1983 Jul; 85(1):12-6. PubMed ID: 6303887
[TBL] [Abstract][Full Text] [Related]
28. The hazardous burden of Herpesviridae in inflammatory bowel disease: the case of refractory severe ulcerative colitis.
Lavagna A; Bergallo M; Daperno M; Sostegni R; Ravarino N; Crocellà L; Ramella A; Rocca R; Torchio B; Cavallo R; Pera A
Dig Liver Dis; 2006 Dec; 38(12):887-93. PubMed ID: 16931197
[TBL] [Abstract][Full Text] [Related]
29. Addition of leukocytapheresis to steroid therapy: is it beneficial in recurrence of moderate-to-severe ulcerative colitis?
Jo Y; Matsumoto T; Mibu R; Iida M
Dis Colon Rectum; 2003 Oct; 46(10 Suppl):S3-9. PubMed ID: 14530652
[TBL] [Abstract][Full Text] [Related]
30. Epidemiology of ulcerative colitis in Israel: a survey of Israeli kibbutz settlements.
Niv Y; Abuksis G; Fraser GM
Am J Gastroenterol; 2000 Mar; 95(3):693-8. PubMed ID: 10710059
[TBL] [Abstract][Full Text] [Related]
31. In vitro cellular cytotoxicity in Crohn's disease and ulcerative colitis: relation with disease activity and treatment, and the effect of recombinant gamma-interferon.
Aparició-Pagés MN; Verspaget HW; Peña AS; Weterman IT; de Bruin PA; Mieremet-Ooms MA; van der Zon JM; van Tol EA; Lamers CB
J Clin Lab Immunol; 1989 Jul; 29(3):119-24. PubMed ID: 2517428
[TBL] [Abstract][Full Text] [Related]
32. Appendectomy is an independent protective factor for ulcerative colitis: results of a multicentre case control study. The Italian Group for the Study of the Colon and Rectum (GISC).
Parrello T; Pavia M; Angelillo IF; Monteleone G; Riegler G; Papi G; D'Incà R; Annese V; Tonelli F; Caprilli R; Pallone F
Ital J Gastroenterol Hepatol; 1997 Jun; 29(3):208-11. PubMed ID: 9646210
[TBL] [Abstract][Full Text] [Related]
33. Increased circulating platelet-neutrophil, platelet-monocyte complexes, and platelet activation in patients with ulcerative colitis: a comparative study.
Pamuk GE; Vural O; Turgut B; Demir M; Umit H; Tezel A
Am J Hematol; 2006 Oct; 81(10):753-9. PubMed ID: 16941615
[TBL] [Abstract][Full Text] [Related]
34. Appendectomy protects against the development of ulcerative colitis but does not affect its course.
Selby WS; Griffin S; Abraham N; Solomon MJ
Am J Gastroenterol; 2002 Nov; 97(11):2834-8. PubMed ID: 12425556
[TBL] [Abstract][Full Text] [Related]
35. Cold-reactive lymphocytotoxins in Crohn's disease and ulcerative colitis. I. Incidence and characterization.
Brown DJ; Jewell DP
Clin Exp Immunol; 1982 Jul; 49(1):67-74. PubMed ID: 6982133
[TBL] [Abstract][Full Text] [Related]
36. [Neutrophil elastase activity in patients with ulcerative colitis].
Poniewierka E; Masłowski L; Wysokiński W; Lubczyńska-Kowalska W; Ciosek W
Wiad Lek; 1994 Feb; 47(3-4):81-3. PubMed ID: 7975646
[TBL] [Abstract][Full Text] [Related]
37. Smoking habits in patients with inflammatory bowel disease.
Benoni C; Nilsson A
Scand J Gastroenterol; 1984 Sep; 19(6):824-30. PubMed ID: 6515319
[TBL] [Abstract][Full Text] [Related]
38. Function of phagocytes in experimentally induced colitis in rabbits. II. The Shwartzman phenomenon in the colon.
Hermanowicz A; Hermel A; Nowak A; Sliwiński Z; Nawarska Z; Borys D; Banaś B
Int Arch Allergy Appl Immunol; 1986; 80(3):245-52. PubMed ID: 3721594
[TBL] [Abstract][Full Text] [Related]
39. The prevalence of hyper- and hypothyroidism in patients with ulcerative colitis.
Casella G; De Marco E; Antonelli E; Daperno M; Baldini V; Signorini S; Sannella F; Morelli A; Villanacci V; Bassotti G
J Crohns Colitis; 2008 Dec; 2(4):327-30. PubMed ID: 21172232
[TBL] [Abstract][Full Text] [Related]
40. Staphylococcal protein A (SpA): a potent in vivo chemotactic agent for rat leucocytes.
Onyia KA
Comp Immunol Microbiol Infect Dis; 1988; 11(1):21-6. PubMed ID: 3383551
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
